West Pharmaceutical Services $WST Q3 net sales up 8.7%, lifts full-year guidance

West Pharmaceutical Services reported Q3 net sales of $874.5 million, up 8.7% year-over-year, with adjusted-diluted EPS of $2.66, up 35.7%. The company raised its full-year 2026 net sales guidance to $3.41-$3.42 billion and adjusted-diluted EPS guidance to $9.38-$9.48. West also repurchased $231 million of stock in the quarter.